IPM Take
The strongest message in the updated AMR plan is that access and stewardship are not opposites. Countries need better diagnostics, quality-assured antimicrobials and infection prevention, while also preventing misuse that drives resistance. That is the implementation trap: restricting antibiotics without ensuring timely access can harm patients, while expanding access without stewardship can accelerate resistance. AMR preparedness now depends on building systems that can do both at the same time.
Executive Summary
In January 2026, WHO submitted the draft updated Global Action Plan on Antimicrobial Resistance 2026 to 2036 to the Executive Board. The plan is intended to guide countries in updating national action plans and to support implementation of the 2024 UN Political Declaration on AMR through a One Health approach. The draft states that bacterial AMR directly caused an estimated 1.14 million deaths in 2021 and was associated with 4.71 million deaths globally. It aims to preserve the ability to treat human, animal and plant diseases through equitable access to safe, effective and quality-assured antimicrobials, while strengthening stewardship, diagnostics, infection prevention, surveillance, governance and accountability.
Why it matters
- Policymakers: Need to update national AMR action plans so access, stewardship, diagnostics and One Health governance are planned together.
- Public authorities / regulators: Must strengthen antimicrobial quality, surveillance, infection prevention, diagnostic capacity and regulation across human, animal and environmental sectors.
- Clinicians / hospitals: Need systems that support the right antimicrobial for the right patient, guided by diagnostics and stewardship rather than either overuse or delayed access.
Previously, AMR policy often swung between two pressures: reducing inappropriate antimicrobial use and improving access where people still die because effective treatment is unavailable. The updated WHO plan makes clear that both are part of the same preparedness agenda.
What has changed is the decade-long policy frame. The 2026 to 2036 draft links AMR to human health, animal health, agriculture, food systems and the environment. It also highlights weak infection prevention, low vaccination coverage, substandard and falsified medicines, limited diagnostic access and insufficient regulatory capacity as drivers of resistance and poor outcomes.
There is no narrow eligibility group. The affected population is global, but the burden and implementation gaps are especially important for low and middle income countries, where access to diagnostics, quality-assured antimicrobials and stewardship capacity can be weakest.
For IPM, this is precision public health: the right antimicrobial, guided by the right diagnostic, delivered to the right patient, under governance that protects both present care and future effectiveness. Access without stewardship is unsafe. Stewardship without access is inequitable. The next AMR decade needs systems that can hold those two realities together.
